News

The advancement of ART24 into the Phase 1 clinical trial was based on its favorable profile exhibited in pre-clinical safety testing, as well as its demonstration of potent

The designation will help investigate the efficacy of Jardiance to minimise the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease. Jardiance, a

Forty Seven and Rocket Pharmaceuticals have entered into a research collaboration for evaluating a new treatment regimen in Fanconi Anemia, a rare paediatric disease. Fanconi Anemia affects the

U.S. Venture Partners (“USVP”) led the round, with participation from new investors including Nextech Invest Ltd., Hunt Investment Group, Pontifax Venture Capital, Colt Ventures LP and NS Investment.

Brii Bio’s funding to Columbia comes in the form of an unrestricted grant to facilitate creating a framework for the formation of strategic collaborations in areas of complementary

The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate -040 trial. Around

The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. NINLARO is an oral proteasome inhibitor, which

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has conducted preclinical pharmacology studies that suggest

IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT